A biopharmaceutical company making treatments for blood cancers and bone marrow disorders, Geron's approved drug RYTELO is given to adults with myelodysplastic syndromes who need blood transfusions. Founded in 1990 by biogerontologist Michael West, the name comes from the Greek word "geron," meaning "elder," reflecting an original focus on the biology of aging. Its work builds on Nobel Prize-winning research into telomeres, chromosome caps often called a "molecular clock."
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -1.89M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.